Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis

Jingyi Zhang(Shenyang Pharmaceutical University), Yongkui Jing(Icahn School of Medicine at Mount Sinai)
Cell Death and Disease
April 20, 2022
Cited by 23


Related Papers